STAMBP and melanoma: Our previous study demonstrated that the combined treatment with αMSH plus the PI3K inhibitor LY294002 caused a pigment retention phenomenon in B16-F10 melanoma cells, normal human melanocytes, and ex vivo skin samples [14].